Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports
| Autor: | Victor B. Nguyen, Sean D. Sullivan, Lisa M. Bloudek, Jens Grueger |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Technology Assessment
Biomedical Cost effectiveness Cost-Benefit Analysis Drug Costs Decision Support Techniques 03 medical and health sciences Drug Utilization Review 0302 clinical medicine Drug approval Humans Medicine 030212 general & internal medicine Retrospective Studies Cost–utility analysis Health economics Actuarial science business.industry 030503 health policy & services Health Policy Public Health Environmental and Occupational Health Value-Based Purchasing Models Economic Value (economics) Quality-Adjusted Life Years 0305 other medical science business |
| Zdroj: | Value in Health. 24:789-794 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2021.01.006 |
| Popis: | Objectives The Institute for Clinical and Economic Review (ICER) is an independent organization that reviews drugs and devices with a focus on emerging agents. As part of their evaluation, ICER estimates value-based prices (VBP) at $50 000 to $150 000 per quality-adjusted life-year (QALY) gained thresholds. We compared actual estimated net prices to ICER-estimated VBPs. Methods We reviewed ICER final evidence reports from November 2007 to October 2020. List prices were combined with average discounts obtained from SSR Health to estimate net prices. If a drug had been evaluated more than once for the same indication, only the more recent VBP was included. Results A total of 34 ICER reports provided unique VBPs for 102 drugs. The net price of 81% of drugs exceeded the $100 000 per QALY VBP and 71% exceeded the $150 000 per QALY VBP. The median change in net price needed to reach the $150 000 per QALY VBP was a 36% reduction. The median decrease in net price needed was highest for drugs targeting rare inherited disorders (n = 15; 62%) and lowest for cardiometabolic disorders (n = 6; 162% price increase). The reduction in net prices needed to reach ICER-estimated VBPs was higher for drugs evaluated for the first approved indication, rare diseases, less competitive markets, and if the drug approval occurred before the ICER report became available. Conclusion Net prices are often above VBPs estimated by ICER. Although gaining awareness among decision makers, the long-term impact of ICER evaluations on pricing and access to new drugs continues to evolve. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect